Safety and immunogenicity after a 30-month boost of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120/MF59 vaccine boost (HVTN 100): A phase 1-2 randomized double-blind placebo-controlled trial.

Autor: Naicker V; South African Medical Research Council, Durban, South Africa., Laher F; Faculty of Health Sciences, Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa., Bekker LG; Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa., Seaton KE; Departments of Surgery and Integrative Immunobiology, Duke Human Vaccine Institute, Durham, North Carolina, United States of America., Allen M; Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America., De Rosa S; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Yates NL; Departments of Surgery and Integrative Immunobiology, Duke Human Vaccine Institute, Durham, North Carolina, United States of America., Mkhize NN; National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.; Faculty of Health Sciences, SAMRC Antibody Immunity Research Unit, University of the Witwatersrand, Johannesburg, South Africa., Saunders K; Departments of Surgery and Integrative Immunobiology, Duke Human Vaccine Institute, Durham, North Carolina, United States of America., Heptinstall J; Departments of Surgery and Integrative Immunobiology, Duke Human Vaccine Institute, Durham, North Carolina, United States of America., Malahleha M; Synergy Biomed Research Institute, East London, South Africa., Mngadi K; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa., Daniels B; South African Medical Research Council, Durban, South Africa., Innes C; Aurum Institute, Klerksdorp Research Centre, Klerksdorp, South Africa., Yu C; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Modise T; National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.; Faculty of Health Sciences, SAMRC Antibody Immunity Research Unit, University of the Witwatersrand, Johannesburg, South Africa., Bekker V; National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.; Faculty of Health Sciences, SAMRC Antibody Immunity Research Unit, University of the Witwatersrand, Johannesburg, South Africa., Grunenberg N; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Furch B; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Miner MD; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Phogat S; Sanofi Pasteur, Swiftwater, Pennsylvania, United States of America.; GSK, Wavre, Belgium., Diazgranados CA; Sanofi Pasteur, Swiftwater, Pennsylvania, United States of America., Gurunathan S; Sanofi Pasteur, Swiftwater, Pennsylvania, United States of America., Koutsoukos M; GSK, Wavre, Belgium., Van Der Meeren O; Previously GSK, Rixensart, Belgium., Roxby AC; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.; University of Washington Departments of Medicine and Global Health, Seattle, Washington, United States of America., Ferrari G; Department of Surgery, Center for Human System Immunology, Duke University School of Medicine, Durham, North Carolina, United States of America., Morris L; National Institute for Communicable Diseases, National Health Laboratory Service, Johannesburg, South Africa.; Faculty of Health Sciences, SAMRC Antibody Immunity Research Unit, University of the Witwatersrand, Johannesburg, South Africa.; Centre for the AIDS Programme of Research in South Africa, Durban, South Africa., Montefiori D; Departments of Surgery and Integrative Immunobiology, Duke Human Vaccine Institute, Durham, North Carolina, United States of America., McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America., Tomaras GD; Departments of Surgery and Integrative Immunobiology, Duke Human Vaccine Institute, Durham, North Carolina, United States of America., Moodie Z; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America.

Publikováno v: PLOS global public health [PLOS Glob Public Health] 2024 Sep 20; Vol. 4 (9), pp. e0003319. Date of Electronic Publication: 2024 Sep 20 (Print Publication: 2024).

Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120.

Autor: Chirenje ZM; Department of Obstetrics and Gynecology, University of California San Francisco, San Francisco, California, USA.; Faculty of Medicine and Health Science, University of Zimbabwe Clinical Trials Research Centre, University of Zimbabwe, Harare, Zimbabwe., Laher F; Perinatal HIV Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Dintwe O; Cape Town HIV Vaccine Trials Network Immunology Laboratory, Cape Town, South Africa.; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Muyoyeta M; Centre for Infectious Diseases Research in Zambia, Livingstone, Zambia., deCamp AC; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., He Z; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Grunenberg N; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Laher Omar F; Cape Town HIV Vaccine Trials Network Immunology Laboratory, Cape Town, South Africa., Seaton KE; Center for Human Systems Immunology, Duke University School of Medicine, Durham, North Carolina, USA.; Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA., Polakowski L; Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA., Woodward Davis AS; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Maganga L; National Institute for Medical Research-Mbeya Medical Research Centre, Mbeya, Tanzania., Baden LR; Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA., Mayer K; Beth Israel Deaconess Medical Center, Harvard University, Boston, Massachusetts, USA.; The Fenway Institute, Fenway Health, Boston, Massachusetts, USA., Kalams S; Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Keefer M; Department of Medicine, University of Rochester, Rochester, NewYork, USA., Edupuganti S; Department of Medicine, Emory University, Atlanta, Georgia, USA., Rodriguez B; Division of Infectious Diseases and HIV Medicine, Department of Medicine, Case Western Reserve University/University Hospitals, Cleveland Medical Center, Cleveland, Ohio, USA., Frank I; School of Medicine, University of Pennsylvania, Philadelphia, USA., Scott H; SanFrancisco Department of Public Health, San Francisco, California, USA., Stranix-Chibanda L; Faculty of Medicine and Health Science, University of Zimbabwe Clinical Trials Research Centre, University of Zimbabwe, Harare, Zimbabwe., Gurunathan S; Sanofi Pasteur, Swiftwater, Pennsylvania, USA., Koutsoukos M; GSK, Wavre, Belgium., Van Der Meeren O; GSK, Rixensart, Belgium., DiazGranados CA; Sanofi Pasteur, Swiftwater, Pennsylvania, USA., Paez C; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Andersen-Nissen E; Cape Town HIV Vaccine Trials Network Immunology Laboratory, Cape Town, South Africa.; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Kublin J; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Ferrari G; Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, USA., Tomaras G; Center for Human Systems Immunology, Duke University School of Medicine, Durham, North Carolina, USA.; Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA., McElrath MJ; Cape Town HIV Vaccine Trials Network Immunology Laboratory, Cape Town, South Africa.; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.

Publikováno v: The Journal of infectious diseases [J Infect Dis] 2024 Aug 16; Vol. 230 (2), pp. e405-e415.

Safety and immunogenicity of a polyvalent DNA-protein HIV vaccine with matched Env immunogens delivered as a prime-boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial.

Autor: Frank I; Division of Infectious Disease, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA., Li SS; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Grunenberg N; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Overton ET; Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL, USA., Robinson ST; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Zheng H; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA; Icon, Burlington, QC, Canada., Seaton KE; Department of Surgery, Duke University, Durham, NC, USA; Department of Immunology, Duke University, Durham, NC, USA; Department of Molecular Genetics and Microbiology, Duke University, Durham, NC, USA; Duke Human Vaccine Institute, Duke University, Durham, NC, USA; Center for Human Systems Immunology, Duke University, Durham, NC, USA., Heptinstall JR; Department of Surgery, Duke University, Durham, NC, USA; Department of Immunology, Duke University, Durham, NC, USA; Department of Molecular Genetics and Microbiology, Duke University, Durham, NC, USA; Duke Human Vaccine Institute, Duke University, Durham, NC, USA; Center for Human Systems Immunology, Duke University, Durham, NC, USA., Allen MA; Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Mayer KH; Division of Infectious Diseases, Beth Israel Deaconess Medical Center, Boston, MA, USA; The Fenway Institute, Fenway Health, Boston, MA, USA., Culver DA; Department of Pulmonary and Critical Care Medicine, Integrated Hospital Care Institute, Cleveland Clinic, Cleveland, OH, USA; Department of Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA., Keefer MC; Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA., Edupuganti S; Hope Clinic of the Emory Vaccine Center, Division of Infectious Diseases, Department of Medicine, School of Medicine, Emory University, Decatur, GA, USA., Pensiero MN; Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Mehra VL; Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., De Rosa SC; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Morris DE; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Wang S; Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA., Seaman MS; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA, USA., Montefiori DC; Department of Surgery, Duke University, Durham, NC, USA; Duke Human Vaccine Institute, Duke University, Durham, NC, USA., Ferrari G; Department of Surgery, Duke University, Durham, NC, USA; Department of Molecular Genetics and Microbiology, Duke University, Durham, NC, USA; Duke Human Vaccine Institute, Duke University, Durham, NC, USA; Center for Human Systems Immunology, Duke University, Durham, NC, USA., Tomaras GD; Department of Surgery, Duke University, Durham, NC, USA; Department of Immunology, Duke University, Durham, NC, USA; Department of Molecular Genetics and Microbiology, Duke University, Durham, NC, USA; Duke Human Vaccine Institute, Duke University, Durham, NC, USA; Center for Human Systems Immunology, Duke University, Durham, NC, USA., Kublin JG; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA., Lu S; Department of Medicine, University of Massachusetts Chan Medical School, Worcester, MA, USA. Electronic address: shan.lu@umassmed.edu.

Publikováno v: The lancet. HIV [Lancet HIV] 2024 May; Vol. 11 (5), pp. e285-e299.

A HIV-1 Gp41 Peptide-Liposome Vaccine Elicits Neutralizing Epitope-Targeted Antibody Responses in Healthy Individuals.

Autor: Erdmann NB; University of Alabama at Birmingham, Birmingham, AL., Williams WB; Duke Human Vaccine Institute, Duke University, Durham, NC.; Department of Surgery, Duke University School of Medicine, Durham, NC., Walsh SR; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA.; Harvard Medical School, Boston, MA., Grunenberg N; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA., Edlefsen PT; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA., Goepfert PA; University of Alabama at Birmingham, Birmingham, AL., Cain DW; Duke Human Vaccine Institute, Duke University, Durham, NC.; Department of Medicine, Duke University School of Medicine, Durham, NC., Cohen KW; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA., Maenza J; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA., Mayer KH; Harvard Medical School, Boston, MA.; Fenway Institute, Boston, MA., Tieu HV; New York Blood Center, New York, NY.; Columbia University, New York, NY., Sobieszczyk ME; Columbia University, New York, NY., Swann E; Division of AIDS, National Institute of Allergy and Immunology, Bethesda, MD., Lu H; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA., De Rosa SC; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA., Sagawa Z; Access to Advanced Health Institute, Seattle, WA., Moody MA; Duke Human Vaccine Institute, Duke University, Durham, NC.; Department of Pediatrics, Duke University School of Medicine, Durham, NC., Fox CB; Access to Advanced Health Institute, Seattle, WA., Ferrari G; Duke Human Vaccine Institute, Duke University, Durham, NC.; Department of Surgery, Duke University School of Medicine, Durham, NC., Edwards RJ; Duke Human Vaccine Institute, Duke University, Durham, NC.; Department of Medicine, Duke University School of Medicine, Durham, NC., Acharya P; Duke Human Vaccine Institute, Duke University, Durham, NC.; Department of Surgery, Duke University School of Medicine, Durham, NC., Alam SM; Duke Human Vaccine Institute, Duke University, Durham, NC.; Department of Medicine, Duke University School of Medicine, Durham, NC., Parks R; Duke Human Vaccine Institute, Duke University, Durham, NC., Barr M; Duke Human Vaccine Institute, Duke University, Durham, NC., Tomaras GD; Duke Human Vaccine Institute, Duke University, Durham, NC.; Department of Surgery, Duke University School of Medicine, Durham, NC., Montefiori DC; Duke Human Vaccine Institute, Duke University, Durham, NC.; Department of Surgery, Duke University School of Medicine, Durham, NC., Gilbert PB; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA., McElrath MJ; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA., Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA., Haynes BF; Duke Human Vaccine Institute, Duke University, Durham, NC.; Department of Medicine, Duke University School of Medicine, Durham, NC., Baden LR; Division of Infectious Diseases, Brigham and Women's Hospital, Boston, MA.; Harvard Medical School, Boston, MA.

Publikováno v: MedRxiv : the preprint server for health sciences [medRxiv] 2024 Mar 18. Date of Electronic Publication: 2024 Mar 18.

Efficacy of Messenger RNA-1273 Against Severe Acute Respiratory Syndrome Coronavirus 2 Acquisition in Young Adults From March to December 2021.

Autor: Stephenson KE; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA., Marcelin JR; Division of Infectious Diseases, Department of Medicine, University of Nebraska Medical Center, Omaha, Nebraska, USA., Pettifor AE; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Janes H; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Brown E; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Neradilek M; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Yen C; Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA., Andriesen J; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Grunenberg N; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Espy N; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Trahey M; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA., Fischer RSB; Department of Epidemiology and Biostatistics, School of Public Health, Texas A&M University, College Station, Texas, USA., DeSouza CA; Department of Integrative Physiology, University of Colorado, Boulder, Colorado, USA., Shisler JL; Department of Microbiology, University of Illinois, Urbana, Illinois, USA., Connick E; Department of Medicine, University of Arizona, Tucson, Arizona, USA., Houpt ER; Division of Infectious Diseases and International Health, University of Virginia, Charlottesville, Virginia, USA., Chu HY; Department of Medicine, University of Washington, Seattle, Washington, USA., McCulloh RJ; Children's Hospital and Medical Center, University of Nebraska Medical Center, Omaha, Nebraska, USA., Becker-Dreps S; Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.; Department of Family Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Vielot NA; Department of Family Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA., Kalbaugh CA; Department of Public Health Sciences, Clemson University, Clemson, South Carolina, USA., Cherabuddi K; Department of Medicine, University of Florida, Gainesville, Florida, USA., Krueger KM; Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., Rosenberg M; Center for Sexual Health Promotion, Indiana University School of Public Health-Bloomington, Bloomington, Indiana, USA., Greenberg RN; Department of Medicine, University of Kentucky, Lexington, Kentucky, USA., Joaquin A; Department of Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, California, USA., Immergluck LC; Department of Microbiology, Biochemistry and Immunology, Morehouse School of Medicine, Atlanta, Georgia, USA., Corey L; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.; Department of Medicine, University of Washington, Seattle, Washington, USA.; Department of Laboratory Medicine, University of Washington,Seattle, Washington, USA., Kublin JG; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, Washington, USA.

Publikováno v: Open forum infectious diseases [Open Forum Infect Dis] 2023 Nov 02; Vol. 10 (11), pp. ofad511. Date of Electronic Publication: 2023 Nov 02 (Print Publication: 2023).